NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free CYTK Stock Alerts $48.51 -0.61 (-1.24%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$48.03▼$49.3650-Day Range$47.86▼$75.0552-Week Range$25.98▼$110.25Volume2.53 million shsAverage Volume2.53 million shsMarket Capitalization$5.09 billionP/E RatioN/ADividend YieldN/APrice Target$74.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside54.4% Upside$74.88 Price TargetShort InterestBearish14.05% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.46Based on 24 Articles This WeekInsider TradingSelling Shares$6.32 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.53) to ($4.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.11 out of 5 starsMedical Sector178th out of 928 stocksPharmaceutical Preparations Industry73rd out of 437 stocks 4.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.05% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Cytokinetics has recently increased by 3.80%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 2.5 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Cytokinetics this week, compared to 8 articles on an average week.Search Interest11 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,319,540.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.53) to ($4.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesMay 8, 2024 | insidertrades.comFady Ibraham Malik Sells 15,547 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockMay 31 at 4:16 AM | americanbankingnews.comTruist Financial Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $70.00May 31 at 3:44 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) PT Lowered to $78.00 at JMP SecuritiesMay 30 at 2:56 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) PT Lowered to $78.00May 29 at 4:00 PM | globenewswire.comCytokinetics to Participate in June Investor ConferencesMay 28, 2024 | globenewswire.comCytokinetics Announces Closing of Public Offering of Common StockMay 28, 2024 | markets.businessinsider.comBuy Rating Justified for Cytokinetics Amid Strong Capital Position and Promising Drug PipelineMay 28, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) to Post Q2 2024 Earnings of ($1.05) Per Share, Leerink Partnrs ForecastsMay 28, 2024 | americanbankingnews.comHC Wainwright Comments on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)May 27, 2024 | finance.yahoo.comIs Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?May 26, 2024 | uk.investing.comCytokinetics shares target cut, cites key financial transactionsMay 25, 2024 | americanbankingnews.comLeerink Partnrs Analysts Lower Earnings Estimates for Cytokinetics, Incorporated (NASDAQ:CYTK)May 25, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Stock Price Down 3% Following Analyst DowngradeMay 24, 2024 | seekingalpha.comCytokinetics Decides To Go It AloneMay 24, 2024 | americanbankingnews.comNeedham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72.00May 24, 2024 | americanbankingnews.comBank of America Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $60.00May 24, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Price Target Lowered to $70.00 at Raymond JamesMay 24, 2024 | americanbankingnews.comHC Wainwright Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $90.00May 24, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Price Target Lowered to $95.00 at BarclaysMay 24, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Shares Gap Down on Analyst DowngradeMay 23, 2024 | markets.businessinsider.comCytokinetics: Strong Buy Rating Backed by Significant Financial Support and Promising PipelineMay 23, 2024 | msn.comWhy Cytokinetics (CYTK) Shares Are FallingMay 23, 2024 | marketwatch.comCytokinetics Shares Drop 17% After Public Offering PricesMay 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)May 22, 2024 | globenewswire.comCytokinetics Announces Pricing of Public Offering of Common StockSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/01/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$74.88 High Stock Price Target$106.00 Low Stock Price Target$50.00 Potential Upside/Downside+54.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-14,141.74% Pretax Margin-14,141.74% Return on EquityN/A Return on Assets-67.32% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio7.19 Sales & Book Value Annual Sales$7.53 million Price / Sales675.47 Cash FlowN/A Price / Cash FlowN/A Book Value($3.78) per share Price / Book-12.83Miscellaneous Outstanding Shares104,850,000Free Float101,289,000Market Cap$5.09 billion OptionableOptionable Beta0.72 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsAvidity BiosciencesNASDAQ:RNAConstellation PharmaceuticalsNASDAQ:CNSTZogenixNASDAQ:ZGNXIntercept PharmaceuticalsNASDAQ:ICPTPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 4,066 shares on 5/28/2024Ownership: 0.048%Farallon Capital Management LLCSold 985,372 shares on 5/24/2024Ownership: 0.098%Cetera Advisors LLCBought 7,579 shares on 5/24/2024Ownership: 0.007%Castleark Management LLCBought 20,980 shares on 5/17/2024Ownership: 0.020%Walleye Trading LLCSold 23,300 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 17 equities research analysts have issued twelve-month target prices for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $106.00. On average, they anticipate the company's share price to reach $74.88 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 on January 1st, 2024. Since then, CYTK shares have decreased by 41.9% and is now trading at $48.51. View the best growth stocks for 2024 here. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by $0.17. The biopharmaceutical company earned $0.84 million during the quarter, compared to analysts' expectations of $0.91 million. The company's quarterly revenue was down 81.8% on a year-over-year basis. During the same period in the prior year, the company earned ($1.38) EPS. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), Fidelity Disruptive Medicine ETF (FMED), SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.56%), Price T Rowe Associates Inc. MD (2.80%), HAP Trading LLC (0.00%), Janus Henderson Group PLC (0.76%), Westfield Capital Management Co. LP (0.70%) and Hood River Capital Management LLC (0.66%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceBill Clinton Backing Biden Replacement???The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss Ratings“This will be one of the biggest revolutions ever.” - NVIDIA CEOBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.